Skip Navigation


European Journal of Heart Failure Advance Access originally published online on June 10, 2009
European Journal of Heart Failure 2009 11(7):709-714; doi:10.1093/eurjhf/hfp078
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/7/709    most recent
hfp078v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gjesdal, O.
Right arrow Articles by Simonsen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gjesdal, O.
Right arrow Articles by Simonsen, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival

Ola Gjesdal1,4,*, Einar Gude1, Satish Arora1, Torbjørn Leivestad3, Arne K. Andreassen1, Lars Gullestad1,4, Lars Aaberge1, Harald Brunvand1, Thor Edvardsen1,4, Odd R. Geiran2,4 and Svein Simonsen1

1 Department of Cardiology, Rikshospitalet, N-0027 Oslo, Norway
2 Department of Thoracic and Cardiovascular Surgery, Rikshospitalet, N-0027 Oslo, Norway
3 Institute of Immunology, Rikshospitalet, N-0027 Oslo, Norway
4 Faculty Division Rikshospitalet, University of Oslo, N-0027 Oslo, Norway

* Corresponding author. Tel: +47 23 07 00 00, Fax: +47 23 07 39 17, Email: ola.gjesdal{at}medisin.uio.no


   Abstract

Aims: There are few studies of the use of intra-aortic balloon pump (IABP) treatment as a bridge to heart transplantation (HTx). This is the first study to compare long-term clinical and haemodynamic outcomes in IABP-treated HTx patients and electively transplanted patients.

Methods and results: This was a retrospective study of all adult HTx recipients between 2001 and 2007. Thirty-two patients (aged 50 ± 13 years) treated with IABP, as a bridge to HTx due to severe hypo-perfusion, were compared with 135 electively transplanted patients (aged 54 ± 11 years). The mean time from onset of IABP to HTx was 21 ± 16 days. Clinical condition improved during IABP treatment. Serum creatinine decreased from 128 ± 56 to 102 ± 29 µmol/L (P < 0.01), aspartate transaminase from 682 ± 1299 to 63 ± 89 U/L (P = 0.01), and ALAT from 483 ± 867 to 126 ± 284 U/L (P = 0.02). Intra-aortic balloon pump treatment related complications were few. Mortality was similar in the IABP and control groups at 30 days post-HTx (6.2 vs.3.7%, P = 0.54), at 1 year (9.4 vs.11.1%, P = 0.80), and beyond. Long-term clinical and haemodynamic indices were similar in the two groups.

Conclusion: Intra-aortic balloon pump treatment stabilizes patients in end-stage heart failure, is safe, well tolerated, and is successful in bridging acutely decompensated patients to transplantation. Complications are few and manageable. Following IABP and HTx, short- and long-term survival, biochemical and invasive and non-invasive haemodynamic outcomes were similar to those in electively transplanted patients.

Key Words: Heart transplantation • Heart failure • Intra-aortic balloon pump • Survival

Received December 16, 2008; Revised April 3, 2009; Accepted April 9, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.